Search

Your search keyword '"Bacigalupo, Andrea"' showing total 14 results
Start Over Author "Bacigalupo, Andrea" Journal american journal of hematology
14 results on '"Bacigalupo, Andrea"'

5. Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen

Author

Chiusolo, Patrizia, primary, Bregante, Stefania, additional, Giammarco, Sabrina, additional, Lamparelli, Teresa, additional, Casarino, Lucia, additional, Dominietto, Alida, additional, Raiola, Anna Maria, additional, Metafuni, Elisabetta, additional, Di Grazia, Carmen, additional, Gualandi, Francesca, additional, Sora, Federica, additional, Laurenti, Luca, additional, Sica, Simona, additional, Barosi, Gianni, additional, Guolo, Fabio, additional, Rossi, Monica, additional, Rossi, Elena, additional, Vannucchi, Alessandro, additional, Signori, Alessio, additional, De Stefano, Valerio, additional, Bacigalupo, Andrea, additional, and Angelucci, Emanuele, additional

Published
2020
Full Text
View/download PDF

6. Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome

Author

Alessandrino, Emilio Paolo, Porta, Matteo G. Della, Malcovati, Luca, Jackson, Christopher H, Pascutto, Cristiana, Bacigalupo, Andrea, van Lint, Maria Teresa, Falda, Michele, Bernardi, Massimo, Onida, Francesco, Guidi, Stefano, Iori, Anna Paola, Cerretti, Raffaella, Marenco, Paola, Pioltelli, Pietro, Angelucci, Emanuele, Oneto, Rosi, Ripamonti, Francesco, Rambaldi, Alessandro, Bosi, Alberto, and Cazzola, Mario

Published
2013
Full Text
View/download PDF

9. First line treatment of aplastic anemia with thymoglobuline in Europe and Asia: Outcome of 955 patients treated 2001-2012

Author

Bacigalupo, Andrea, primary, Oneto, Rosi, additional, Schrezenmeier, Hubert, additional, Hochsmann, Britta, additional, Dufour, Carlo, additional, Kojima, Seiji, additional, Zhu, Xiaofan, additional, Chen, Xiaojuan, additional, Issaragrisil, Surapol, additional, Chuncharunee, Suporn, additional, Chul Jeong, Dae, additional, Giammarco, Sabrina, additional, Teresa Van Lint, Maria, additional, Zheng, Yizhou, additional, and Vallejo, Carlos, additional

Published
2018
Full Text
View/download PDF

10. Haploidentical bone marrow transplantation in patients with advanced myelodysplastic syndrome

Author

Varaldo, Riccardo, primary, Raiola, Anna Maria, additional, Di Grazia, Carmen, additional, Aquino, Sara, additional, Beltrami, Germana, additional, Bregante, Stefania, additional, Cruciani, Fabio, additional, Dominietto, Alida, additional, Ghiso, Anna, additional, Giannoni, Livia, additional, Gualandi, Francesca, additional, Ibatici, Adalberto, additional, Lamparelli, Teresa, additional, Marani, Carlo, additional, Van Lint, Maria Teresa, additional, Santini, Valeria, additional, Bacigalupo, Andrea, additional, and Angelucci, Emanuele, additional

Published
2017
Full Text
View/download PDF

11. High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk‐oriented consolidation: A critical review of a 10‐year, single‐center experience in younger, non M3 AML patients

Author

Guolo, Fabio, primary, Minetto, Paola, additional, Clavio, Marino, additional, Miglino, Maurizio, additional, Di Grazia, Carmen, additional, Ballerini, Filippo, additional, Pastori, Giordana, additional, Guardo, Daniela, additional, Colombo, Nicoletta, additional, Kunkl, Annalisa, additional, Fugazza, Giuseppina, additional, Rebesco, Barbara, additional, Sessarego, Mario, additional, Lemoli, Roberto Massimo, additional, Bacigalupo, Andrea, additional, and Gobbi, Marco, additional

Published
2016
Full Text
View/download PDF

12. Successful bone marrow transplantation in children with severe aplastic anemia using HLA‐partially matched family donors

Author

Locatelli, Franco, primary, Porta, Fulvio, additional, Zecca, Marco, additional, Pedrazzoli, Paolo, additional, Maccario, Rita, additional, Giani, Simona, additional, Vitale, Vito, additional, Martinetti, Myriam, additional, Mazzolari, Evelina, additional, Lanfranchi, Arnalda, additional, Nespoli, Luigi, additional, Bacigalupo, Andrea, additional, and Severi, Francesca, additional

Published
1993
Full Text
View/download PDF

14. Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen.

Author

Chiusolo P, Bregante S, Giammarco S, Lamparelli T, Casarino L, Dominietto A, Raiola AM, Metafuni E, Di Grazia C, Gualandi F, Sora F, Laurenti L, Sica S, Barosi G, Guolo F, Rossi M, Rossi E, Vannucchi A, Signori A, De Stefano V, Bacigalupo A, and Angelucci E

Subjects
Adult, Aged, Allografts, Busulfan administration & dosage, Disease-Free Survival, Female, Follow-Up Studies, Humans, Male, Melphalan administration & dosage, Middle Aged, Splenectomy, Survival Rate, Thiotepa administration & dosage, Hematopoietic Stem Cell Transplantation, Primary Myelofibrosis mortality, Primary Myelofibrosis therapy, Transplantation Chimera, Transplantation Conditioning
Abstract

The aim of this retrospective study was to assess the rate of full donor chimerism (F-DC) in patients with myelofibrosis, prepared for an allogeneic stem cell transplant, with one or two alkylating agents. We analyzed 120 patients with myelofibrosis, for whom chimerism data were available on day +30. There were two groups: 42 patients were conditioned with one alkylating agent (ONE-ALK), either thiotepa or busulfan or melphalan, in combination with fludarabine, whereas 78 patients were prepared with two alkylating agents, thiotepa busulfan and fludarabine (TBF). Patients receiving TBF were older (57 vs 52 years), were less frequently splenectomized pre-HSCT (31% vs 59%), had more frequently intermediate-2/high DIPSS scores (90% vs 74%), were grafted more frequently from alternative donors (83% vs 33%) and received more frequently ruxolitinib pre-HSCT (26% vs 7%). The proportion of patients with F-DC on day +30, in the TBF vs the ONE-ALK group, was respectively 87% vs 45% (P < .001). The 5-year cumulative incidence of relapse was 9% in the TBF group, vs 43% for the ONE-ALK group (P < .001). The 5-year actuarial disease-free survival was 63% for TBF and 38% for the ONE-ALK group (P = .004). In conclusion, early full donor chimerism is a prerequisite for long term control of disease in patients with myelofibrosis, undergoing an allogeneic HSCT. The combination of two alkylating agents in the conditioning regimen, provides a higher chance of achieving full donor chimerism on day+30, and thus a higher chance of long term disease free survival., (© 2020 Wiley Periodicals LLC.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results